355
Participants
Start Date
February 26, 2020
Primary Completion Date
April 30, 2024
Study Completion Date
April 30, 2026
Prospective monitoring of a large variety of parameters
Patients will be recruited during an inpatient pulmonary rehabilitation program. This setting offers a unique opportunity to study the phenomenon of an acute exacerbation of the Chronic Obstructive Pulmonary Disease prior to the first visible clinical sign and further on to have a follow up of the underlying mechanisms. All COPD patients that are referred to the reference center for a rehabilitation program will be included after providing written informed consent. Prospectively, a wide range of measurements will be collected. If a patient develops an acute exacerbation there will be a comprehensive diagnostic assessment to differentiate between pulmonary, cardiac or cardio-pulmonary reasons for the exacerbation. The clinical diagnosis of an AECOPD will be made by a pulmonologist according to criteria of international guidelines within the first 24h of clinical symptoms suggestive of an exacerbation.
Schoen Klinik Berchtesgadener Land, Schönau am Königssee
GlaxoSmithKline GmbH & Co. KG (Munich, Germany)
UNKNOWN
Coordinating Center for Clinical Trials (KKS; Philipps-University of Marburg, Germany)
UNKNOWN
Research Office (Biostatistics), Paracelsus Medical University (Salzburg, Austria)
UNKNOWN
Fraunhofer ITEM, Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (Hannover, Germany)
UNKNOWN
Institute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics, Philipps University Marburg (Marburg, Germany)
UNKNOWN
Schön Klinik Berchtesgadener Land
OTHER